EP4232581A1 — Methods and compositions for treating primary hyperoxaluria
Assigned to Alnylam Pharmaceuticals Inc · Expires 2023-08-30 · 3y expired
What this patent protects
The present invention provides methods and compositions for treating a pediatric subject having primary hyperoxaluria and methods for preventing at least one symptom in a pediatric subject having primary hyperoxaluria. The methods include administering to the subject a therapeuti…
USPTO Abstract
The present invention provides methods and compositions for treating a pediatric subject having primary hyperoxaluria and methods for preventing at least one symptom in a pediatric subject having primary hyperoxaluria. The methods include administering to the subject a therapeutically effective amount or a prophylactically effective amount of an RNAi agent, e.g. , double-stranded RNAi agent, targeting HAO1.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.